Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04325035 · ClinicalTrials.gov registry record · Phase 2
The Safety and Efficacy of Istaroxime for Pre-Cardiogenic Shock
A Phase 2 study, sponsored by Windtree Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
NCT04325035 is a Phase 2 study that has completed, run by Windtree Therapeutics. The registered enrollment target is 90 participants.
The verdict
NCT04325035, a Phase 2 study, has completed, sponsored by Windtree Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
Study Summary
This is a pilot, multinational, randomized, double-blind, placebo-controlled, 2-part safety and efficacy study. Subjects will consist of patients hospitalized for acute decompensated heart failure with persistent hypotension.
Interventions
- DRUG Placebo
- DRUG Istaroxime
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2020-09-28 |
| Est. Completion | 2024-10-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04325035
The ClinicalTrials.gov registry entry for NCT04325035 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Windtree Therapeutics, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04325035 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04325035 about?
NCT04325035 is a clinical study titled "The Safety and Efficacy of Istaroxime for Pre-Cardiogenic Shock". This is a pilot, multinational, randomized, double-blind, placebo-controlled, 2-part safety and efficacy study. Subjects will consist of patients hospitalized for acute decompensated heart failure with persistent hypotension.
What is the current status of trial NCT04325035?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2020-09-28. Estimated completion is 2024-10-30.
What interventions are being tested in trial NCT04325035?
The interventions under investigation include: Placebo (DRUG), Istaroxime (DRUG).
Who is sponsoring clinical trial NCT04325035?
This trial is sponsored by Windtree Therapeutics, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.